We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+29.17%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$355M
AUM Growth
+$73.9M
Cap. Flow
+$27.7M
Cap. Flow %
7.79%
Top 10 Hldgs %
95.82%
Holding
25
New
3
Increased
7
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
ONCR
Oncorus, Inc.
ONCR
+$38.9M
2
OVID icon
Ovid Therapeutics
OVID
+$975K
3
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$615K
4
AKUS
Akouos Inc
AKUS
+$477K
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$335K

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$8.55M
2
DTIL icon
Precision BioSciences
DTIL
+$1.33M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$954K
4
KZR
Kezar Life Sciences
KZR
+$621K
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$534K

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
3 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
1
DELISTED
Repare Therapeutics
RPTX
$86.9M 24.47%
2,532,150
+1,656
+0.1% +$49.5K
ONCR
2
DELISTED
Oncorus, Inc.
ONCR
$54.3M 15.3%
+1,679,906
New +$38.9M
PLRX icon
3
Pliant Therapeutics
PLRX
$71.2M
$53.5M 15.07%
2,354,799
+2,508
+0.1% +$62.9K
LRMR icon
4
Larimar Therapeutics
LRMR
$421M
$32.4M 9.14%
1,515,148
– –
KROS icon
5
Keros Therapeutics
KROS
$223M
$30.6M 8.62%
433,852
-135,606
-24% -$8.55M
FRLN
6
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$24.9M 7%
90,738
+2,447
+3% +$615K
INZY
7
DELISTED
Inozyme Pharma
INZY
$20.5M 5.79%
995,396
-13,721
-1% -$327K
AKUS
8
DELISTED
Akouos Inc
AKUS
$17.3M 4.86%
870,897
+24,500
+3% +$477K
ORTX
9
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12.7M 3.57%
293,119
– –
DTIL icon
10
Precision BioSciences
DTIL
$232M
$7.11M 2%
28,412
-5,416
-16% -$1.33M
AMWL icon
11
American Well
AMWL
$200M
$6.29M 1.77%
12,418
– –
OVID icon
12
Ovid Therapeutics
OVID
$572M
$1.91M 0.54%
827,260
+209,168
+34% +$975K
CRVS icon
13
Corvus Pharmaceuticals
CRVS
$1.24B
$1.75M 0.49%
490,877
-92,355
-16% -$372K
GTHX
14
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.11M 0.31%
62,000
-22,000
-26% -$329K
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
$987K 0.28%
22,800
+6,800
+43% +$335K
KZR
16
DELISTED
Kezar Life Sciences
KZR
$705K 0.2%
13,500
-11,164
-45% -$621K
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$642K 0.18%
5,921
-1,079
-15% -$133K
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$617K 0.17%
5,500
-1,000
-15% -$105K
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.59B
$415K 0.12%
3,000
-4,500
-60% -$534K
BLUE
20
DELISTED
bluebird bio
BLUE
$346K 0.1%
618
– –
XBI icon
21
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$54K 0.02%
+10,000
New +$1.28M
DTIL icon
22
CALL
Precision BioSciences
DTIL
$232M
$8K ﹤0.01%
+333
New +$81.6K
GBT
23
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8K ﹤0.01%
20,000
+10,000
+100% +$493K
MYOK
24
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-7,000
Closed -$954K
LVGO
25
DELISTED
Livongo Health, Inc. Common Stock
LVGO
– –
-3,640
Closed -$510K

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, CHI Advisors held 25 positions worth $355M, up 26% from $281M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

CHI Advisors deployed $27.7M of net new capital in Q4 2020, opening 3 new positions and adding to 7 existing holdings. Its largest new stake was Oncorus, Inc.: 1,679,906 shares worth $54.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $8.55M trimmed.

  • CHI Advisors's largest Q4 2020 buy was Oncorus, Inc.: 1,679,906 shares worth $54.3M.
  • CHI Advisors added most to Ovid Therapeutics in Q4 2020, an estimated $975K increase.
  • CHI Advisors's biggest Q4 2020 reduction was Keros Therapeutics, cutting an estimated $8.55M.
  • CHI Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $954K.
  • CHI Advisors's ten largest holdings make up 96% of its $355M portfolio in Q4 2020.
  • CHI Advisors opened 3 new positions and closed 2 in Q4 2020.
  • CHI Advisors's portfolio value rose 26% quarter-over-quarter to $355M.

Based on CHI Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.